Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Free Cash Flow (2016 - 2025)

Adma Biologics (ADMA) has disclosed Free Cash Flow for 13 consecutive years, with $34.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 27.19% year-over-year to $34.6 million, compared with a TTM value of $27.8 million through Dec 2025, down 74.81%, and an annual FY2025 reading of $27.8 million, down 74.81% over the prior year.
  • Free Cash Flow was $34.6 million for Q4 2025 at Adma Biologics, up from -$1.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $47.5 million in Q4 2024 and bottomed at -$37.1 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$2.9 million, with a median of -$9.0 million recorded in 2022.
  • The sharpest move saw Free Cash Flow skyrocketed 728.77% in 2024, then crashed 433.98% in 2025.
  • Year by year, Free Cash Flow stood at -$37.1 million in 2021, then soared by 70.04% to -$11.1 million in 2022, then surged by 247.38% to $16.4 million in 2023, then soared by 189.38% to $47.5 million in 2024, then fell by 27.19% to $34.6 million in 2025.
  • Business Quant data shows Free Cash Flow for ADMA at $34.6 million in Q4 2025, -$1.1 million in Q3 2025, and $18.7 million in Q2 2025.